Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at 1,153.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US. Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end. The product and innovation pipeline is advancing materially: Zydus plans to file an NDA for Saroglitazar Magnesium in the US imminently, has achieved several biosimilar and specialty milestones including a first‑in‑class Menkes disease approval (Zycubo), and holds licensing deals for large‑molecule biosimilars and a CE mark for its Andy robotic surgical system. Strategic M&A and partnerships are reshaping growth engines: full consolidation of Comfort Click doubled down Consumer Wellness scale (Q3 consumer revenue ▲113% YoY), acquisition of US biologics facilities from Agenus enables a Bio CDMO roadmap, and management retained a Rs. 5,000 crore QIP approval as an optional funding lever for future acquisitions. Geographic and portfolio diversification is visible: Pharma remains ~81% of sales with North America contributing 41% of revenues, India branded formulations outperformed the market with 14% growth, International Markets accelerated (▲38% YoY), and consumer wellness and MedTech are emerging, higher‑growth adjacencies supporting margin and top‑line resilience.

Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.85 and a high of ₹1,205.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zydus Lifesciences Ltd has a market capitalization of approximately 1,15,012.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zydus Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,15,012.19 Cr, Zydus Lifesciences Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zydus Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 25.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Zydus said saroglitazar (1 mg) met the primary endpoint at 52 weeks, delivering a 48.5% treatment difference versus placebo and higher biochemical response (56.7% vs 9.8%).

Revenue from operations rose 22% YoY to ₹8,017.0 crore, EBITDA fell 7.6% YoY to ₹1,929.4 crore, and reported net profit declined 35.9% YoY to ₹939.8 crore.

Zydus Lifesciences reported consolidated net profit of Rs 1,272.5 crore in Q4 FY26, up 8.7% to 9% year-on-year from Rs 1,171 crore.

The stock reacted to disclosures of USFDA observations at certain facilities, prompting an immediate risk reassessment by traders despite the company stating no data integrity issues.